Lisa VanWagner

Has grant

Associate Professor and Director of Clinical Research

University of Texas Southwestern Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Lisa VanWagner is an Associate Professor and Director of Clinical Research at the University of Texas Southwestern Medical Center. Her research areas include hepatology, cardiovascular health, and the implications of metabolic dysfunction-associated liver disease. She has contributed to various significant studies, exploring topics such as heart failure prediction related to liver health and the management of liver transplant candidates with high cardiac risk. Dr. VanWagner's work is pivotal in understanding the intricate relationships between liver disease and cardiovascular health in patient populations.

Recent Grants

Grant: Close

Derivation and validation of a cardiac risk index in liver transplantation

Open Date: 2013-09-01

Close Date: 2014-08-31

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (16)

Thomas Kerr

Associate Professor of Medicine

University of Texas Southwestern Medical Center

UNITED STATES

Lisa VanWagner

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Post-Transjugular Intrahepatic Portosystemic Shunt Right Atrial Pressure and Left Atrial Volume Index Predict Heart Failure and Mortality: Dual Center Experience

Sex and gender differences in metabolic dysfunction-associated liver disease

Does the heart whisper before the liver crashes? NT-proBNP and the prediction of ACLF

Cardiovascular Health Trajectories and Prevalent Metabolic Dysfunction‐Associated Steatotic Liver Disease in Midlife: The CARDIA Study

ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study

Summary of a consensus conference on heart-liver transplantation

Financial burden in a US cohort of patients with HCC

Management of the liver transplant candidate with high cardiac risk: Multidisciplinary best practices and recommendations

Where you live matters: Area deprivation predicts poor survival and liver transplant waitlisting

Controversies in terlipressin and transplantation in the United States: How do we MELD the two?

Predictive performance of CAR-OLT and CAD-LT scores for post-transplant adverse cardiovascular events in a large transplant center

Aerobic and Muscle-Strengthening Physical Activity, Television Viewing, and Nonalcoholic Fatty Liver Disease: The CARDIA Study

Biliary atresia and liver transplantation in the United States: A contemporary analysis

Management of Stroke in Patients With Chronic Liver Disease: A Practical Review

Geographic Variation in NAFLD Prevalence and Subspecialty Care Utilization Among Insured Adults in the United States

Multicenter assessment of hypertension management among liver transplantation recipients

Monitoring cardiovascular risk factors after liver transplantation may improve outcomes

Lipoprotein Levels in Early Adulthood and NAFLD in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study

Blood Pressure Variability Early After Liver Transplantation Predicts Long‐Term Mortality

Coronary Artery Disease Assessment During Evaluation for Liver Transplantation: How Much Does It Matter?

Collaborators (16)

Thomas Kerr

Yi-Ju Li

David Jacobs

Sumeet K. Asrani

Daniel McDonough

David Kleiner

Juliet Emamaullee

Sarah Lieber

Kiarri N. Kershaw

Marina Serper

Pamela Schreiner

John Carr

John Entwistle

James Slaughter

Jennifer Lai

Zachary Pope

Make your next move.